We want to change the status quo of lipid-based targeted delivery of various drug payloads which is limiting its broader therapeutic applications.
We are pioneering next next-generation polymer-based delivery technology platform that is able to deliver multiple drug payloads by targeting specific tissues or cells and potentially overcome well-known challenges faced by lipid nanoparticle-based products. Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads.
ACM Biolabs’ Tunable Platform (ATP™) is a polymer/lipid hybrid, non-viral delivery platform that offers the flexibility to deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ACM Biolabs has programs targeting multiple organs, tissues, and immune cells.
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering (IMRE, A*STAR) and also at Nanyang Technological University).
Pharmacologist. Vaccines Expert with more than 30 years of experience of R&D.
Doctorat at the Université catholique de Louvain, Belgium. Leading function at GSK, Abivax, NeoVacs, Imcyse, and Amyl Therapeutics. CEO at Vaccibio Consulting.
Founder of the Erber Group, an Austrian animal nutrition company (now part of DSM), which consists of more than 50 affiliates in all continents. He is also founder of the SAN Pacific Investments Group. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs’ Board of Directors.
Sang Bin is currently the managing director of Ritz Venture Capital, a Singapore based family fund that focuses in supporting early-stage companies. He has over 30 years of experience in venture investments as well as mentorship within the academic community. With his background in engineering and business, he is a strong supporter of applying cutting edge technology and cultivating talents to address some of the key challenges in the world in the near future.
David has wide ranging experience gained in over 30 years in the lifesciences industry. His expertise includes finance, business development and strategy gained across big pharma, vaccines, biotech, medtech and synthetic biology. David currently serves on the board of EnteroBiotix Ltd and was most recently the CFO of Valneva where he led several financings including its Nasdaq IPO in 2021. He served on the Board of Synpromics until its acquisition in 2019, have driven the development of the company from 2011.
Professor & Chair, Clinical Immunology, University of Zurich, Director, Department of Immunology, University Hospital Zurich.
PhD. Managed the Micro- and Nano-systems group of 50 R&D staff in the Singapore research institute where the polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. Has worked with Dr Nallani on ACM since 2011.
Katherine Schultheis joined ACM Biosciences in 2022 as Head of Discovery Research with a strong background of preclinical development of DNA based vaccines and immunotherapeutics. Katherine has more than 10 years of academic and corporate research experience in the fields of infectious diseases, autoimmunity and oncology. She was heading a research team at Inovio Pharmaceuticals in San Diego, California, before moving back to the greater Basel area in 2021. Katherine obtained her Master’s level degree in Biochemistry from University of Potsdam, Germany.
Yvonne has over 30 years’ experience in the biopharmaceutical industry and significant technical, commercial and project management expertise in the development and commercialisation of oral and parenteral small molecule and biological products.
Prior to joining Cilatus, Yvonne was the Vice President of Technical Operations Project Management and Strategy at Horizon Pharma, overseeing all project managers responsible for managing tech transfers for both a number of small molecule oral products and biologics in late-stage development and commercial settings. She was instrumental in developing project planning systems, processes and tools in constantly changing pharmaceutical development and operational environments.
At Alkermes Pharma she was the Senior Director, Head of Project Management, responsible for the planning, budgeting and tracking of development and commercial product support projects at the Athlone facility, Ireland. At Elan Drug Technologies, she held the position of Senior Director, Head of Project Management, and she was responsible for planning, budgeting and tracking of development and commercial product support projects across 3 locations in Ireland and the US.
Yvonne holds a BSc. degree in Biochemistry and Chemistry, and PhD in Endocrinology from University College Dublin.
Since joining Cilatus, Yvonne has been acting as the CMC team leader for a small molecule for a client and she has been engaged in CDMO/CMO searches. For ACM Biosciences Yvonne is the CMC Project Lead.
Jenny has more than 20 years’ experience in executive management of companies in the biotechnology and biopharmaceutical industry.
She has served on the Boards of a number of listed and unlisted companies and is currently a Non-Executive Director of Neuren Pharmaceuticals Ltd (ASX:NEU) and Aeris Environmental Ltd (ASX:AEI). Jenny is a graduate of the Harvard Business School General Manager Program and the Australian Institute of Company Directors.
Before joining ACM Biolabs, Qiwei was an audit manager with experience in SMEs and subsidiaries of MNCs of various industries. He is also a member of the Institute of Singapore Chartered Accountants and CPA Australia.
Prior to joining ACM Biolabs, Melvin received his PhD in Materials Science and Engineering from Nanyang Technological University in 2023. His PhD research focused on the fabrication and characterization of biomimetic nanoparticles for drug and RNA delivery.
Dr. Liu received her PhD in chemical and biomolecular engineering from National University of Singapore (NUS). She has more than 15 years of research and development experience in Biomedical science and Bioengineering. She has generated 5 patents and 42 papers in reputable journals including Nature communications and Advanced Materials.
Jian Hang Lam holds a Ph.D. from the Yong Loo Lin School of Medicine, National University of Singapore. He was trained in pre-clinical dengue vaccine development and gained experience in virology and immunology, with special focus on investigating correlates of protection.
Ser Yue Loo is a Senior Scientist at ACM Biolabs. Prior to joining ACM Biolabs, Ser Yue carried out her postdoctoral fellowship at Genome Institute of Singapore, where she conducted research on therapeutics for treatment of triple negative breast cancer. Her work led to the successful translation from bench to bedside with the initiation of a clinical trial BEXMET in National Cancer Centre Singapore.
Loo Ser Yue obtained her PhD from Yong Loo Lin School of Medicine at National University of Singapore in 2014.
Gaurav joined ACM Biolabs in 2021, after completing his PhD research in the field of point-of-care diagnostics from the School of Material Science and Engineering at NTU.
Yan Jun Lee is a Scientist at ACM Biolabs. She obtained her PhD from Nanyang Technological University, Singapore in 2021. She then carried out her postdoctoral fellowship at National University of Singapore. She has conducted neuroscience studies in molecular and system settings throughout her academics training.
Anivind Kaur Bindra is a Scientist at ACM Biolabs. She obtained bachelor’s and master’s degrees in Chemistry from University of Delhi, India in 2015. Thereafter, from her research internship at Defence Research and Development Organization, India, she got interested into the cancer drug delivery field. She further pursued Ph.D. in Chemistry from Nanyang Technological University, Singapore in 2021. During Ph.D. and Postdoctoral training, her research interests included the design and development of functional organic-inorganic hybrid nanomaterials for nanomedicine.
Senior research associate at ACM Biolabs. Obtained a bachelor’s degree in Chemistry and Biological Chemistry in 2019 at the Nanyang Technological University.
Research Assistant at ACM Biolabs. Obtained a diploma in Chemical Engineering in 2015 and Bachelor’s Degree in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.
Research Assistant at ACM Biolabs. Obtained a diploma in Medicinal Chemistry in 2017 and a degree of Bachelor of Science in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.”
Fong Jing Yi is a Research Assistant at ACM Biolabs. She obtained a diploma in Pharmaceutical Science and a degree in Pharmaceutical Engineering, focusing in Biologics where she performed her 8 months internship at ACM Biolabs, working on accessing the stability of formulations at different storage conditions and durations.
We are looking for highly motivated specialists – take a look at our career offers
Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads.
Our data show that ATPs can deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ATP™ has the potential to transform targeted delivery of various drug payloads.
At ACM Biolabs, we are developing innovative medicines using our targeted ATP™ delivery platform. Our non-viral, ATP™-based nanocarriers are suitable for diverse drug payloads with various routes of administration, including mucosal delivery.
ATP™ can target the right tissues and cells. This powerful toolbox has the potential to address a broad range of diseases.
Our first clinical program is ongoing, and we are working on additional indications to demonstrate the ability to deliver multiple modalities.
Phase 1 completed. Polymersomes formulated with spike protein co- administered with polymersomes formulated CpG 7909, as a Covid booster vaccine.
IND ready polymersomes with CpG combined with anti-PD1 in lung cancer patients as targeted immuno therapy.
Preclinical evaluation of broader innate agonist and lung targeted chemotherapy.
Preclinical evaluation of polymersomes with monoclonal antibodies suitable for topical application to the retina.
At ACM Biolabs we are driven to change the status quo of limited therapeutic applications offered by lipid-based delivery. We are developing diverse treatments with multiple drug modalities with our modular ATPTM platform.
* Platform Clinical Validation
** IIT with National Cancer Center Singapore (NCCS)
We are currently building a high quality and motivated team to develop our polymer-based delivery technology and bring innovative medicines to patients with high unmet medical need. Working at the intersection of pre-clinical and clinical research as a part of multidisciplinary team We we are looking for candidates with expertise in mRNA technologies, nano-technology, chemistry of lipids- and polymer-based delivery formulations and analytical methods. Interested applicants should please forward their resumé / CV to email@example.com